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to estimate associated direct health costs comparing the use of paracalcitol and 
cinacalcet plus low dose vitamin D over a 5-years horizon and using the Italian 
National Health System perspective. The model was developed using parameters 
from literature and assumption discussed with clinicians. National tariffs and costs 
from literature were used to value drug use, dialytic treatment, hospitalizations and 
transplant. One-way sensitivity analyses for model inputs were conducted. Costs 
and effects were discounted at 3% annum. Results: Considering 13.311 candidate 
subjects for each treatment strategy, results from the model showed a decrease in 
direct health care costs from 1.782.921.351 Euro to 1.622.357.209 Euro in favour of 
paricalcitol over 5 years. Particularly, paricalcitol produced an overall saving in drug 
costs for more than 51 millions Euro while the other direct health costs related to 
dialysis, hospitalization and transplant were reduced by approximately 109 mil-
lions Euro. ConClusions: In light of the high economic burden of end stage renal 
disease mainly associated with dialysis and transplant the use of paricalcitol for 
the treatment of IPTS in these patients represents a valid alternative not only from 
a clinical point of view but also from an economic point of view.
PUK6
AnAlysis Of BUdget imPAct Of AnemiA cOrrectiOn in rUssiAn PAtients 
With chrOnic Kidney diseAse
Ryazhenov V.V., Gorokhova S.G.
I. M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To analyze budget impact of strategies of anemia correction with 
different stimulators of erythropoiesis in patients with chronic kidney disease 
(СКD). Methods: Pharmacoeconomic analysis included cost modelling for a new 
strategy for patients with CKD and anemia that includes the use of continuous 
erythropoietin receptor activator (CERA) compared with traditional darbepoetin alfa 
(as described in ARCTOS study). The model included two stages: 1. Estimation of 
costs in 18 week correction period (phase 1 study), and 2. estimation of costs and 
effectiveness within 10 week period (phase 2 study). The costs were evaluated in 
two groups of 100 people, the first with CERA and the second with darbepoetin alfa. 
According to ARCTOS study, fewer patients treated with continuous erythropoietin 
receptor activator (CERA) required transfusion procedures compared with darbepoetin 
alfa (2.5% and 6.8%, respectively). The drugs in the study were to be administered 
under medical supervision in a day hospital. The time horizon of the study was 28 
weeks. Results: The costs of a phase 1 was 53 187.21 in CERA group and 104 528.88 
RUB in darbepoetin alfa group. The costs were almost identical in the second phase. 
The costs in darbepoetin alfa group were 2.7 times higher compared with CERA in 
respect of blood transfusion and 2 times higher in respect of drug administration. 
The cost of pharmacotherapy in CERA group was significantly lower than in group 
of darbepoetin alfa. Total costs in CERA group were 1, 7 times lower than those for 
darbepoetin alfa. ConClusions: The study demonstrates that administration of 
CERA is the most economically effective strategy for the treatment of patients with 
chronic kidney disease in Russia. It is associated with considerably lower costs com-
pared to darbepoetin alfa.
PUK7
BUdget imPAct evAlUAtiOn Of treAtment With A lOW PrOtein diet 
And KetOAnAlOgUes Of essentiAl AminOAcids fOr PrediAlysis 
PAtients in rUssiAn federAtiOn
Serpik V.G., Kulikov A.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To evaluate budget impact of low protein diet (LPD) and ketoana-
logues supply of predialysis patients in Russian Federation from Pharmacoeconomic 
perspective. Methods: Analytic decision-making model and budget impact 
analyses (BIA) were performed. Direct costs (ketoanalogues, hemodialysis, peri-
toneal dialysis, etc.) were considered. Two patients groups were compared in the 
model: ketoanalogues and LPD was administrated for the first arm in predialysis 
stage, while second arm started in the model of dialysis patients. Results of ret-
rospective efficacy analysis state, that administration of keto-analogues and LPD 
delays start of dialysis at least for one year. The following prices were used: rates of 
State medical insurance fund, Sechenov First Moscow State Medical University hos-
pitals price lists, NHS medication prices. Exchange rate: 1EURO = 40 RUB. Results: 
The first year annual costs were 23186 EURO per patient for the patients group on 
dialysis and 8620 EURO for the group of ketoanalogues. The results of BIA have 
shown that administration of ketoanalogues and LPD provides cost-saving of 14562 
EURO per patient in the first year compared with dialysis group. Total cost-saving per 
patient in the group of ketoanalogues and LPD over 5-year period was 12895 EURO 
compared with the dialysis group. ConClusions: Budget impact assessment has 
shown, that ketoanalogues and LPD in Russian Federation is a preferable technology 
and provides cost-saving of 12895 EURO over five years per patient.
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An ecOnOmic mOdel tO investigAte the BUdget imPAct in sPAin Of 
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objeCtives: Treatment options for patients for whom urinary incontinence (UI) 
due to idiopathic overactive bladder (OAB) is inadequately managed by anticho-
linergic therapy are limited, and can be expensive, invasive and inefficacious. This 
can lead to a significant economic burden to hospitals and health care systems. 
OnabotulinumtoxinA may provide an effective and minimally-invasive treatment 
option for OAB. An economic model was developed to investigate potential cost 
savings associated with the use of OnabotulinumtoxinA – as an adjunct to best-
supportive care (BSC) – to manage OAB rather than other treatment options in 
Spain. Methods: A prevalence-based, deterministic budget impact model with a 
five-year time horizon was developed from the perspective of the Spanish health care 
objeCtives: Automated peritoneal dialysis (APD) has been increasingly used since 
payment scheme was expanded to cover APD machine in addition to the continuous 
ambulatory peritoneal dialysis (CAPD) in the benefit package of National Health 
Insurance Program in May of 2008. This study aims to compare the health outcome 
between patients who used APD and CAPD. Methods: The including criteria were 
patients treated by APD or CAPD identified in National Health Insurance Research 
Database (NHIRD) during 2001-2010. The excluding criteria were patients who were 
treated by hemodialysis for more than 3 months before PD, or younger than 18 
years old, or received kidney transplant before. The CAPD patients and APD patients 
were identified and matched according to their propensity score predicted by age, 
gender, comorbid conditions, Charlson Comorbid Index, medication history, and 
premiums wages in the year of treatment initiation. There were 2,287 APD and 
2,287 CAPD patients entered the final analysis. The Kaplan-Meier curve and the 
Cox proportional hazard regression were performed to examine the differences 
in mortality rate, technique failure rate and incident rate of peritonitis between 
APD and CAPD. Results: There are significant differences in mortality rate (0.76% 
vs. 0.65% per patient month, p= 0.02), in technique failure rate (1.07% vs. 0.87% per 
patient month, p< 0.001), and in incidence rate of peritonitis (1.94% vs. 2.14% per 
patient month, p< 0.01) between APD and CAPD cases. When compared with CAPD, 
patients treated by APD posed higher risk in death and technique failure but no 
difference in the incidence of the 1stperitonitis with hazard ratios of 1.18 (CIs: 1.03-
1.34), 1.22 (CIs: 1.09-1.37) and 0.98 (CIs: 0.88-1.10), respectively. ConClusions: The 
APD patients seemed to have higher mortality rate and technique failure rate than 
CAPD patients, however, APD patients had lower incident rate of peritonitis than 
CAPD patients in Taiwan.
PUK3
A stUdy tO Assess diseAse PrOgressiOn tO esrd Within A yeAr in 
PAtients With AdvAnced cKd
Kumar P., Nair M., Prabhu R., Bairy M.
Manipal University, Manipal, India
objeCtives: Aimed at determining the time period for the progression to ESRD and 
also to find out the major risk factors for early progression to ESRD. Methods: A 
retrospective cohort study was conducted in a tertiary care teaching hospital. The 
data was collected from medical record dept. for the last two years (2012 and 2013) 
in hospital. Demographic details and clinical parameters of ESRD patients with 
major risk factors for early progression to ESRD were collected using the descriptive 
statistics feature of SPSS v20.0. Results: A total of 240 patients were included in 
the study. The mean age of the population was found to be 54.6±14.2 years. Majority 
of the population were males (74.83%). Hypertension 67.1%, Diabetes 47.1% and 
anemia 40.83% were the most prominent risk factors present in the study popula-
tion. More than half of the population (72.5%) took more than a year to progress to 
ESRD. ConClusions: The study revealed that males are at a higher risk of ESRD 
with half of the study cohort consisted of elderly patients (above 50 years of age). 
The study results concluded that hypertension is the most common risk factor for 
ESRD followed by diabetes and anemia. Most of the CKD patients took more than 
one year to progress to ESRD (72.5%). This information help physicians and patients 
inform decisions regarding preparation for renal replacement therapy in patients 
with advanced CKD.
PUK4
Be cAUtiOUs Of triPle WhAmmy!!!
Zulkifly H., Abdul Wahab M.S., Shaharuddin S., Chiau Ming L., Mat Zaid H.
Universiti Teknologi MARA, Selangor, Malaysia
objeCtives: This study was aimed to identify the occurrence of concomitant pre-
scribing of NSAIDs, ACE Inhibitors (ACEI) and diuretics known as triple whammy 
received by out-patients at a Malaysian teaching hospital. It also aimed to identify the 
relationship between prescriptions of triple whammy with specific age. Methods: 
A retrospective, observational study was performed in a general teaching hospital. 
The patients’ prescriptions (January-March 2012) from the outpatient pharmacy 
department that were prescribed with NSAIDs, ACE Inhibitors (ACEI) and diuretics 
were reviewed and recorded. The association between the prescriptions with age was 
investigated. Statistical analysis was done using SPSS with significance difference 
determined by p value of < 0.05. Results: Four hundred and twenty four patients 
(56.1% male) were included. Four hundred and twenty two patients were taking one or 
more of NSAIDs, ACEI and diuretic and only 2 patients were taking all three. Majority 
of our patients (40.1%) received the combination of ACEI and diuretics. Combination 
of ACEI and diuretics were mainly (21.7%) prescribed to patients above 65 years old 
(p= 0.362). ConClusions: The occurrence of triple whammy at a teaching hospital 
during the period of data collection is low. This is indeed a good predictor of safe pre-
scribing of drugs among physicians as concomitant use of these three medications 
may impair renal function especially in the elderly and dehydrated patients. Majority 
of the patients that were prescribed with combination of diuretics and ACEI are above 
65 years old, therefore proper monitoring of their renal function and the hydration 
status should be performed to reduce the risk of renal insufficiency in the future.
UrinAry/Kidney disOrders – cost studies
PUK5
A BUdget imPAct AnAlysis (BiA) Of the Use Of PAricAlcitOl fOr the 
treAtment Of secOndAry hyPerPArAthyrOidism (shPt) in end stAge 
renAl diseAse PAtients
Lorenzoni V., Pierotti F., Turchetti G.
Scuola Superiore Sant’Anna, Pisa, Italy
objeCtives: Budget impact analysis (BIA) of the use of paricalcitol versus alterna-
tive treatment for the management of secondary hyperparathyroidism (SHPT) in 
end stage renal disease patients. Methods: A Markov model was used to simulate 
the evolution of end stage renal disease patients trough transplant and death and 
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bases (MEDLINE, EMBASE, SCIENCE CITATION INDEX, NHSEED, HEED, CEA REGISTRY, 
RePEc, HTA database) for manuscripts published between January 2003 and November 
2013. Results were assessed for relevance by two reviewers. For eligible studies, data 
extracted included objectives, costing methodology, sources of data, disaggregated 
and aggregated costs, and conclusions. Results: Of 2094 de-duplicated references 
identified from the combined search, 57 manuscripts remained after review of titles/
abstracts and 40 after full-text review. The majority (n= 35) of studies used retrospec-
tive data; the most common study country was the US (n= 16); most studies (n= 36) 
reported direct costs only. There were four national level costing studies. Societal costs 
for ESRD in Canada totalled $CAN 1.857 billion (2000); cost of RRT in England was £780 
million (2009–2010); total public budgetary impact of Spain’s RRT programme was 
€ 1,829 million (including indirect costs) in 2010; health costs of ESRD patients with 
diabetes was $3,611 million in the US and £184.5 million in the UK in 2001. Annual per-
patient ESRD health care costs ranged from $US 36,917 (PPP, 2004) in Australia, to $US 
96,014 (2002) in US patients with diabetes. Studies also reported national and patient 
level costs for transplant and dialysis. ConClusions: A number of COI studies have 
quantified the cost of ESRD and demonstrate the substantial economic burden associ-
ated with the management of these patients.
PUK13
cOst-Utility And vAlUe Of infOrmAtiOn (vOi) AnAlyses On the 
feAsiBility Of A fUtUre rAndOmised cOntrOlled triAl (rct) Of 
invAsive UrOdynAmic testing PriOr tO sUrgery fOr stress UrinAry 
incOntinence in WOmen
Homer T.1, Vale L.1, Shen J.1, Hilton P.2
1Newcastle University, Newcastle, UK, 2Newcastle upon Tyne Hospitals NHS Foundation Trust, 
Newcastle, UK
objeCtives: To assess the feasibility and VOI of conducting a definitive RCT to deter-
mine whether invasive urodynamic testing (IUT) is cost-effective compared with 
clinical assessment in women prior to surgery for stress (SUI) or stress predominant 
mixed urinary incontinence (MUI) and to rehearse the economic evaluation for a 
definitive RCT. Methods: Cost-utility analysis was performed alongside a pilot RCT. 
222 participants were randomised to receive IUT (‘IUT’ arm) or clinical assessment 
(‘no IUT’ arm) before surgery. Health service resource use, costs, utility values (from 
EQ-5D-3L and SF-12) and quality-adjusted life years (QALYs) were calculated. Expected 
value of sampling information (EVSI) analysis was used to determine the expected 
net gain (ENG) of additional information and the optimal sample size needed to 
maximise ENG in a future trial. Results: At 6 months the average cost incurred in 
the ‘IUT’ arm was £154 less than the ‘no IUT’ arm (95% bootstrapped CI -315 to 24) 
and there was no evidence of a difference in effects (-0.019 QALYs, 95% bootstrapped 
CI -0.0258 to 0.0133). ‘IUT’ generated an incremental cost per QALY of £8090. A sto-
chastic analysis showed that at a zero-willingness to pay threshold the IUT was 96% 
likely to be cost-effective. The VOI analysis suggested there would be added value 
from additional research to confirm which treatment is more efficient. The ENG was 
estimated to be £91m and to maximise ENG a sample size of 105 complete cases in 
each treatment arm is required. ConClusions: There was no significant difference 
in QALYs between study arms, the ‘no IUT’ arm incurred a higher average cost but 
only short-term NHS costs were considered. Our results should be interpreted with 
caution due to the limitations within our analysis. The EVSI analysis confirmed that 
there is additional value to be gained from a definitive study in this area.
PUK14
cic Users’ Preference fOr cAtheters redUcing the Uti freqUency
Neovius K.E., Lundqvist T.
Wellspect HealthCare, Göteborg, Sweden
objeCtives: To investigate the preference among individuals practicing clean inter-
mittent catheterization (CIC) on a daily basis for urinary catheters that can reduce 
the frequency of urinary tract infections (UTIs). Methods: A questionnaire was 
sent by e-mail to 769 catheter users from Germany, Italy, Sweden, the UK and the 
USA through a database held by Wellspect HealthCare. The participants were asked 
to assume a situation in which they use their current catheter but have the choice 
to switch to a similar catheter, which hypothetically would reduce the frequency 
of UTIs including possible complications. Either every fourth or every second UTI 
could be avoided. The participants’ willingness-to-pay for the new catheter was 
collected by letting them choose to spend either one of eleven explicit monthly 
amounts from € 0-€ 100 or any other amount in an open answer. The participants 
also reported their UTI frequency. Only individuals stating that they were “certain” 
or “very certain” regarding their answers were included in the analyses. Results: 
429 (response rate 56%) individuals returned the questionnaire, of which 278 (65%) 
were certain or very certain regarding their answers. The proportion of respondents 
with ≤ 1 UTI/y and > 1 UTI/y were 47% and 53%, respectively. The respondents were 
willing to spend on average € 16 each month to avoid every fourth UTI and € 22 each 
month to avoid every second UTI. The willingness-to-pay was higher among the 
users with > 1 UTI/y both to avoid every fourth and every second UTI (€ 21 vs € 11 and 
€ 30 vs € 15, respectively). These differences in willingness-to-pay were statistically 
significant (p< 0.05).ConClusions: The CIC users in this study, who practice inter-
mittent catheterization on a daily basis, expressed a clear preference for catheters 
that could help to decrease the frequency of urinary tract infections (UTI).
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Maniadakis N.6
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system. The model took into account the cost of drugs, disposables (e. g. incontinence 
pads) and devices, procedures, monitoring costs, and the cost of managing adverse 
events. Model input data were derived from the Spanish Ministry of Health, published 
and unpublished clinical studies, clinical guidelines, and expert opinion. Results: In 
the Spanish population, an estimated 96,360 individuals were eligible for treatment 
with OnabotulinumtoxinA for OAB. Compared to a current treatment pattern in which 
5% of patients received OnabotulinumtoxinA, increasing OnabotulinumtoxinA usage 
annually from 10% in year 1 to 30% in year 5 resulted in an estimated cost saving of 
€ 26.4 million over five years. This saving represented a 4.7% decrease in overall spend-
ing compared to the current treatment pattern. Increased drug acquisition costs were 
entirely offset by savings due to decreased use of incontinence pads and anticholiner-
gic therapy. ConClusions: Costs associated with inadequate management of UI due 
to OAB are significant and avoidable. Our model estimated that managing patients 
with OnabotulinumtoxinA may reduce the economic burden to the Spanish health 
care system, with increased acquisition costs of OnabotulinumtoxinA completely 
offset by savings due to decreased resource use.
PUK10
the imPAct Of cArdiOvAscUlAr diseAse And tyPe 2 diABetes mellitUs 
On sOciAl cOst in chrOnic Kidney diseAse PAtients in itAly
Bellelli S., Turchetti G.
Scuola Superiore Sant’Anna, Pisa, Italy
objeCtives: Chronic kidney disease (CKD) is leading condition of several comorbidi-
ties with additional social economic burden. The study aims to estimate the economic 
impact of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) on the 
social cost of a patient with CKD (stage IV and V pre-dialyses) in Italy. Methods: All 
adult outpatients in charge of 14 main Hospitals Centers in Tuscany Region have been 
enrolled during 7 week in the cross sectional study. Direct medical costs have been 
estimated using tariff for laboratory test, diagnostic exams, visits and hospitalization 
and price for drugs. Non medical costs included the cost of diet, patients and car-
egivers travel expenses, domestic help and informal care. The loss of productivity of 
patients and caregivers have been estimated as indirect costs using the human capital 
approach. The incremental effects of having comorbidities on social cost of CKD were 
estimated by multivariate Generalized Linear Models (log link, Gamma family) adjust-
ing for gender, age and stage of CKD. Costs are expressed in Euro 2012. Results: 
Among 484 CKD patients enrolled, CVD and T2DM have been found respectively in 
214 (44%) and 171 (35%) patients. The raw estimated mean annual social costs were 
€ 11,375 (± € 7,480) per patient with CKD-CVD and € 11,627 (± € 7,657) per patient with 
CKD-T2DM. Direct non medical costs and indirect costs accounted respectively for 
31% and 23% of social cost for CKD-CVD and 30% and 22% for CKD-T2DM. The incre-
mental effects of having comorbidities on the overall social cost of CKD were € 2,928 
(95% CI: € 1,680-€ 4,176, p= 0.000) for CVD and € 2,640 (95% CI: € 1,301-€ 3,979, p= 0.000) 
for T2DM. ConClusions: CVD and T2DM significantly increase the social cost of 
CKD due to the rise of the medical component. However the burden of the disease is 
mainly sustained by patients, their families and the productivity system.
PUK11
the ecOnOmic cOst Of UrinAry trAct infectiOns in the cOmmUnity: 
resUlts frOm irelAnd
Callan A., O’Shea E., Galvin S., Duane S., Corry O., SIMPle Team T., Vellinga A.
NUI Galway, Galway, Ireland
objeCtives: Urinary tract infections (UTIs) are the second most common bacterial 
infection in primary care and are often treated empirically with antibiotics. However, 
outside of the United States, there has been a lack of systematic cost-of-illness stud-
ies to assess the economic cost of UTIs in the community. The objective of this study 
was to estimate the economic cost of UTIs in Ireland from the perspective of the 
health service. Methods: We conducted a secondary analysis of a dataset which 
contained information on adult patients (excluding pregnant women) presenting to 
their General Practitioner (GP) with a suspected UTI. Data was collected from 22 GP 
practices in the West of Ireland over a 9 month period from September 2009 to May 
2010. Results from microbiological analysis to determine a positive urine culture 
were obtained from the University Hospital Galway laboratory. Health care costs were 
estimated on the basis of GP consultation costs, antibiotic costs, laboratory costs and 
secondary inpatient and outpatient costs. The latter was acquired from national clini-
cal data on discharges in acute hospitals. Results: Of the 2,850 GP consultations, 
almost 70% of the urine samples showed no laboratory evidence of a UTI. 57% of 
the patients were prescribed an antibiotic and 11% of patients re-consulted within 
one month. Total primary care costs (including antibiotics) to treat suspected UTIs 
across the 22 practices was approximately € 343,000 annually. Extrapolating results 
to a national level, the annual estimated primary care costs are approximately 
€ 19.2 million. The annual cost of UTIs in secondary care is low at approximately 
€ 155,000. ConClusions: Suspected UTIs are a common reason to attend primary 
care services in Ireland. From the health service perspective, the overall economic 
cost of UTIs is mainly driven by primary care costs with comparatively low second-
ary care costs.
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A revieW Of cOst Of illness stUdies in PAtients With end stAge renAl 
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Paczkowski R.1, Norrbacka K.2, Van Brunt K.3, Kennedy-Martin T.4
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objeCtives: End-stage renal disease (ESRD) is a debilitating medical condition of 
chronic kidney failure. In ESRD, the kidneys are permanently impaired and patients 
require renal replacement therapy (RRT). In order to understand the economic bur-
den of ESRD, this scoping literature review was undertaken to identify published 
cost of illness (COI) studies in ESRD. Methods: The search strategy identified stud-
ies quantifying the economic burden of ESRD in selected countries (USA, Canada, 
Australia, Japan, UK, France, Germany, Spain, and Italy). We searched electronic data-
